Premium
Impetigo Contagiosa III. Comparative Efficacy of Oral Erythromycin and Topical Mupirocin
Author(s) -
Barton Leslie L.,
Friedman Allan D.,
Sharkey Angela M.,
Schneller Daniel J.,
Swierkosz Ella M.
Publication year - 1989
Publication title -
pediatric dermatology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.542
H-Index - 73
eISSN - 1525-1470
pISSN - 0736-8046
DOI - 10.1111/j.1525-1470.1989.tb01012.x
Subject(s) - impetigo , mupirocin , medicine , erythromycin , dermatology , antibiotics , staphylococcus aureus , microbiology and biotechnology , methicillin resistant staphylococcus aureus , biology , bacteria , genetics
Ninety‐seven patients with impetigo were prospectlvely enrolled in a study to determine the comparative efficacy of systemic and topical antibiotic therapy. After obtaining a bacterial culture from a representative losion, the children were randomized to receive seven days of either oral erythromycin or topical mupirocin administered three times daiiy. Staphylococcus aureus aione was Isoiated from 51% and in association with group A β‐hemoiytic streptococci (GABS) from 29%; GABS aione was isoiated from 4% of patients. Of 48 children who received erythromycln, 43 (90%) were citnicaily improved or cured, and 11 of 17 were bacteriologicaliy cured. Of 49 children who received mupirocin, 47 (96%) were clinicaily improved or cured, and 10 of 14 were bacterioiogicaiiy cured. At three week foliow‐up, clinical cure rates and number of secondary househoid cases of impetigo were equivaient In both treatment groups. Mupirocin appears to be a weil‐toierated, aibeit expensive, aiternative to erythromycin for the treatment of impetigo.